P D Zenobi
Overview
Explore the profile of P D Zenobi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin X, Zenobi P
Ophthalmologica
. 2001 Mar;
215(2):117-23.
PMID: 11244342
Background: The purpose of this work was to describe the anterior chamber and iris anomalies as well as to evaluate the effects of recombinant human insulin-like growth factor-I (rhIGF-I) on...
2.
Accuracy of devices for self-monitoring of blood glucose including hypoglycemic blood glucose levels
Zenobi P, Keller A, Glatz Y
Diabetes Care
. 1995 Apr;
18(4):587-8.
PMID: 7497881
No abstract available.
3.
Zenobi P, Glatz Y, Keller A, Graf S, Riesen W, Schoenle E, et al.
Eur J Endocrinol
. 1994 Sep;
131(3):251-7.
PMID: 7921209
Severe insulin resistance type A is due to mutations in the insulin receptor gene and is characterized by glucose intolerance or diabetes mellitus, despite extreme hyperinsulinemia, virilization and acanthosis nigricans....
4.
FROESCH E, Zenobi P, Hussain M
Horm Res
. 1994 Jan;
42(1-2):66-71.
PMID: 7959637
The administration of rhIGF-I in appropriate doses leads to a decrease of insulin and growth hormone secretion and to an increase of insulin sensitivity. In type 2 diabetic patients, IGF-I...
5.
Padayatty S, Orme S, Zenobi P, Stickland M, Belchetz P, Grant P
Thromb Haemost
. 1993 Dec;
70(6):1009-13.
PMID: 8165592
In vitro studies have shown that insulin and IGF-1 releases the fibrinolytic inhibitor plasminogen activator inhibitor-1 (PAI-1) from cells of hepatic origin. To investigate the effects of IGF-1 on fibrinolysis:...
6.
Zenobi P, Holzmann P, Glatz Y, Riesen W, FROESCH E
Diabetologia
. 1993 May;
36(5):465-9.
PMID: 8314453
Type 2 (non-insulin-dependent) diabetes mellitus is associated with increased glucose, insulin, total and VLDL-triglyceride, and often total and LDL-cholesterol levels which promote vascular disease. Recombinant human insulin-like growth factor-I which...
7.
Zenobi P, Riesen W, Roder M, FROESCH E
J Clin Invest
. 1992 Dec;
90(6):2234-41.
PMID: 1469083
Hyperglycemia, hyperinsulinemia, and insulin resistance cause vascular disease in type 2 diabetes mellitus. Dietary treatment alone often fails and oral drugs or insulin enhance hyperinsulinemia. In previous studies, an intravenous...
8.
Zenobi P, Graf S, Ursprung H, FROESCH E
J Clin Invest
. 1992 Jun;
89(6):1908-13.
PMID: 1601998
Insulin-like growth factor-I (IGF-I) and insulin interact with related receptors to lower plasma glucose and to exert mitogenic effects. Recombinant human IGF-I (rhIGF-I) was recently shown to decrease serum levels...
9.
Schoenle E, Zenobi P, Torresani T, WERDER E, ZACHMANN M, FROESCH E
Diabetologia
. 1991 Sep;
34(9):675-9.
PMID: 1955101
The syndrome of type A insulin resistance is encountered in young women and is characterized by glucose intolerance or frank diabetes mellitus, endogenous hyperinsulinism, insensitivity to insulin administration, acanthosis nigricans...
10.
Zenobi P
Schweiz Med Wochenschr
. 1991 Apr;
121(14):475-81.
PMID: 2035004
Insulin (I) preparations used formerly contained a large number of protein contaminants which are thought to be immunogenic and, hence, caused lipodystrophy, I-allergy and sometimes antibody-mediated I-resistance in many patients....